Research programme: epidermolysis bullosa gene therapies - Abeona Therapeutics

Drug Profile

Research programme: epidermolysis bullosa gene therapies - Abeona Therapeutics

Alternative Names: AAV DJCOL7A1; EB-201

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abeona Therapeutics
  • Developer Abeona Therapeutics; Epidermolysis Bullosa Research Partnership; Stanford University
  • Class Gene therapies
  • Mechanism of Action Collagen type VII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Epidermolysis bullosa

Most Recent Events

  • 30 Mar 2017 Abeona Therapeutics has patent protection for EB 201 in USA
  • 30 Mar 2017 Abeona Therapeutics has patents pending for AAV capsid proteins in Europe
  • 16 Aug 2016 Abeona Therapeutics enters into agreement with EB Research Partnership and Stanford University for the development of therapies for Epidermolysis bullosa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top